NCT04604899View on ClinicalTrials.gov

Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

March 22, 2022

Study Completion Date

March 22, 2022

Conditions

Retinitis Pigmentosa

Interventions

BIOLOGICAL

human retinal progenitor cells

single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)

Trial Locations (3)

90074

Retina-Vitreous Associates Medical Group, Los Angeles

92697

Gavin Herbert Eye Inst, Univ Cal Irvine, Irvine

02114

Ophthalmic Consultants of Boston, Boston

All Listed Sponsors

collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

jCyte, Inc

INDUSTRY

NCT04604899 - Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa | Biotech Hunter | Biotech Hunter